KRYSTAL-17: Adagrasib Combinations in Patients with KRAS G12C Mutation
Condition: Non-Small Cell Lung Cancer
Sponsor: Mirati Therapeutics, Inc.
Full Title
Protocol 849-017: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Study Treatment
KRAS G12C inhibitor adagrasib in combination with standard chemo/immunotherapy.
Eligibility/Info
Unresectable or metastatic KRAS G12C mutant non-squamous non-small cell lung cancer that has not been treated in the metastatic setting.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
